In a randomized double-blinded study of 62 COPD subjects, systemic delivery of MSCs resulted in a significant decrease in levels of circulating CRP in patients who had elevated CRP levels at initiation of the study90. This evidence concerns the gene CRP and chronic obstructive pulmonary disease.